Similar articles

• [Mortality of premature infants before and after the treatment of respiratory distress syndrome].

  Sinios A. Sinios A. Monatsschr Kinderheilkd (1902). 1971 Jan;119(1):32-6. Monatsschr Kinderheilkd (1902). 1971. PMID: 5547110 German. No abstract available.
• Serial studies of lung volume and VA-Q in hyaline membrane disease.

  Tori CA, Krauss AN, Auld PA. Tori CA, et al. Pediatr Res. 1973 Feb;7(2):82-8. doi: 10.1203/00006450-197302000-00003. Pediatr Res. 1973. PMID: 4688500 No abstract available.
• [Respiratory pathology of the premature infant].

  Menguy C. Menguy C. Soins Gynecol Obstet Pueric Pediatr. 1992 Dec-1993 Jan;(139-140):22-7. Soins Gynecol Obstet Pueric Pediatr. 1992. PMID: 1308631 French. No abstract available.
• [Pulmonary surfactant: anti-atelectasis factor].

  Ouellet Y. Ouellet Y. Laval Med. 1970 May;41(5):627-30. Laval Med. 1970. PMID: 4928481 Review. French. No abstract available.
• [For or against the early use of nasal continuous positive pressure and exogenous surfactant in hyaline membrane disease. Physiopathologic arguments].

  Storme L, Truffert P, Rakza T, Lequien P. Storme L, et al. Arch Pediatr. 1999 May;6(5):549-55. doi: 10.1016/s0929-693x(99)80564-8. Arch Pediatr. 1999. PMID: 10370813 Review. French.